🇪🇺 Abilify MyCite® in European Union

Abilify MyCite® (Abilify MyCite®) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005062
  • Marketing authorisation holder: Otsuka Pharmaceutical Netherlands B.V.
  • Local brand name: Abilify MyCite
  • Indication: Treatment of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence
  • Status: withdrawn

Read official source →

Other Psychiatry approved in European Union

Frequently asked questions

Is Abilify MyCite® approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Abilify MyCite® in European Union?

Otsuka Pharmaceutical Netherlands B.V. holds the EU marketing authorisation.